ATE556707T1 - Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits - Google Patents

Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits

Info

Publication number
ATE556707T1
ATE556707T1 AT04759288T AT04759288T ATE556707T1 AT E556707 T1 ATE556707 T1 AT E556707T1 AT 04759288 T AT04759288 T AT 04759288T AT 04759288 T AT04759288 T AT 04759288T AT E556707 T1 ATE556707 T1 AT E556707T1
Authority
AT
Austria
Prior art keywords
inhibitors
phosphodiesesterase
treatment
cognitive deficit
cognitive
Prior art date
Application number
AT04759288T
Other languages
German (de)
English (en)
Inventor
Timothy Tully
Filippo Cavalieri
Original Assignee
Cold Spring Harbor Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab filed Critical Cold Spring Harbor Lab
Application granted granted Critical
Publication of ATE556707T1 publication Critical patent/ATE556707T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Magnetic Ceramics (AREA)
  • Inorganic Insulating Materials (AREA)
AT04759288T 2003-04-08 2004-04-08 Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits ATE556707T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/410,508 US20040224316A1 (en) 2000-08-10 2003-04-08 Augmented cognitive training
PCT/US2004/010876 WO2004091609A2 (en) 2001-08-10 2004-04-08 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit

Publications (1)

Publication Number Publication Date
ATE556707T1 true ATE556707T1 (de) 2012-05-15

Family

ID=37416211

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04759288T ATE556707T1 (de) 2003-04-08 2004-04-08 Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits

Country Status (7)

Country Link
US (2) US20040224316A1 (https=)
EP (4) EP2340831B1 (https=)
JP (1) JP4833834B2 (https=)
AT (1) ATE556707T1 (https=)
CA (1) CA2521839C (https=)
ES (3) ES2403333T3 (https=)
WO (1) WO2004091609A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
ATE526020T1 (de) * 2000-08-10 2011-10-15 Cold Spring Harbor Lab Gesteigertes kognitives training
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8975216B2 (en) * 2006-03-30 2015-03-10 Pacific Biosciences Of California Articles having localized molecules disposed thereon and methods of producing same
BRPI0711816A2 (pt) * 2006-05-19 2011-12-13 Helicon Therapeutics Inc inibidores fosfodiesterase 4 para rehabilitação motora e cognitiva
CA2680414A1 (en) * 2007-03-12 2008-09-18 Biolipox Ab Piperidinones useful in the treatment of inflammation
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds
JP2010527243A (ja) * 2007-05-15 2010-08-12 ヘリコン セラピューティクス，インコーポレイテッド 低分子干渉ＲＮＡ（ｓｉＲＮＡ）を用いた記憶形成に関わる遺伝子の同定方法
KR20100029079A (ko) * 2007-05-15 2010-03-15 헬리콘 테라퓨틱스 인코퍼레이티드 Ｇｐｒ12의 저해로 인지 질환을 치료하는 방법
JP5049713B2 (ja) * 2007-09-14 2012-10-17 株式会社コナミデジタルエンタテインメント ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
JP5789511B2 (ja) * 2008-07-18 2015-10-07 ダート ニューロサイエンス （ケイマン） エルティーディー 記憶剤の評価のための方法およびシステム
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
US20150050626A1 (en) * 2013-03-15 2015-02-19 Dart Neuroscience, Llc Systems, Methods, and Software for Improving Cognitive and Motor Abilities
EP3125900A1 (en) * 2014-03-28 2017-02-08 Algiax Pharmaceuticals GmbH Treatment of cognitive disorders
JP2017141222A (ja) * 2016-02-09 2017-08-17 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤及びそのスクリーニング方法
CN116963773A (zh) 2021-01-21 2023-10-27 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5479508A (en) * 1991-05-22 1995-12-26 Zenith Electronics Corp. Method of operating a pay per view television system
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
HU225869B1 (en) 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
US5681735A (en) 1992-04-10 1997-10-28 Fox Chase Cancer Center Transcription control element for increasing gene expression in myoblasts
KR970705562A (ko) * 1994-08-29 1997-10-09 오노다 마사요시 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof)
US5619249A (en) * 1994-09-14 1997-04-08 Time Warner Entertainment Company, L.P. Telecasting service for providing video programs on demand with an interactive interface for facilitating viewer selection of video programs
US5929223A (en) * 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
CA2202087C (en) 1994-10-07 2011-12-06 Timothy P. Tully Cloning and characterizing of genes associated with long-term memory
US5652749A (en) * 1995-02-03 1997-07-29 International Business Machines Corporation Apparatus and method for segmentation and time synchronization of the transmission of a multiple program multimedia data stream
US5793410A (en) * 1995-05-26 1998-08-11 Hyundai Electronics America Video pedestal network
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
PT936923E (pt) * 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology Supressao de tnfalfa e il-12 em terapia
TR199901653T2 (xx) * 1997-01-15 1999-10-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Fitalazinonlar.
WO2000014083A1 (en) 1998-09-09 2000-03-16 Inflazyme Pharmaceuticals Ltd. SUBSTITUTED η-PHENYL-Δ-LACTONES AND ANALOGS THEREOF AND USES RELATED THERETO
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
AU764005B2 (en) 1999-02-25 2003-08-07 Merck Frosst Canada & Co. PDE IV inhibiting compounds, compositions and methods of treatment
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
ATE526020T1 (de) * 2000-08-10 2011-10-15 Cold Spring Harbor Lab Gesteigertes kognitives training
DK1540335T3 (da) * 2002-08-19 2010-07-26 Helicon Therapeutics Inc Screeningsfremgangsmåder til kognitive forstækere

Also Published As

Publication number Publication date
EP2156831B1 (en) 2013-02-27
EP2340831B1 (en) 2014-09-10
CA2521839A1 (en) 2004-10-28
WO2004091609A2 (en) 2004-10-28
US20040224316A1 (en) 2004-11-11
EP2340831A1 (en) 2011-07-06
EP1631281B1 (en) 2012-05-09
EP1631281A2 (en) 2006-03-08
ES2403283T3 (es) 2013-05-17
US20060247252A1 (en) 2006-11-02
EP2156831A1 (en) 2010-02-24
US8097647B2 (en) 2012-01-17
CA2521839C (en) 2014-08-05
HK1087351A1 (en) 2006-10-13
ES2403333T3 (es) 2013-05-17
ES2509093T3 (es) 2014-10-17
EP2116240B1 (en) 2013-02-27
JP4833834B2 (ja) 2011-12-07
WO2004091609A3 (en) 2007-08-16
JP2006524243A (ja) 2006-10-26
HK1159514A1 (en) 2012-08-03
EP2116240A1 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
ATE556707T1 (de) Phosphodiesesterase 4 inhibitoren zur behandlung eines kognitiven defizits
WO2005048953A3 (en) Amide derivatives as kinase modulators
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
EP1626730A4 (en) METHOD, DEVICE AND COMPOSITION FOR TREATING ACNE
ATE286028T1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE602004017037D1 (de) 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose
DE60237725D1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE415968T1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
DE602004005814D1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE602004025808D1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
DE60231507D1 (de) Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
ATE359783T1 (de) Aroylpyrrolheteroeryl und methanole zur behandlung von störungen des zentralnervensystems
WO2007028151A3 (en) Surgical devices and related methods thereof
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
DE602005019341D1 (de) System zur Behandlung von Sterilisationskassetten mit visuellem Dual-Kode Leser
ATE420071T1 (de) 2- (1h-indolylsulfanyl) -arylaminderivate zur verwendung bei der behandlung von affektiven psychosen, schmerzen, dem hyperkinetischen syndrom des kindesalters (adhd) und stressharninkontinenz
NO20053903D0 (no) Nukleotidlipidesterderivater.
DE602004013540D1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
DE60318081D1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson